Aspire BioPharma Company Insiders
| ASBP Stock | 0.10 0.03 23.08% |
Aspire BioPharma employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Discussion of Aspire BioPharma's management performance can provide insight into the enterprise performance.
Aspire BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of (1.9511) % which means that it has lost $1.9511 on every $100 spent on assets. This is way below average. Aspire BioPharma's management efficiency ratios could be used to measure how well Aspire BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aspire BioPharma's Return On Capital Employed is relatively stable compared to the past year. As of 01/12/2026, Return On Equity is likely to grow to 7.69, though Return On Tangible Assets are likely to grow to (92.56). As of 01/12/2026, Total Current Liabilities is likely to grow to about 2 M, while Liabilities And Stockholders Equity is likely to drop slightly above 126.5 K.As of 01/12/2026, Common Stock Shares Outstanding is likely to drop to about 51.2 MAspire BioPharma holds a total of 138.45 Million outstanding shares. Aspire BioPharma shows 13.96 percent of its outstanding shares held by insiders and 2.68 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
As of 01/12/2026, Dividend Paid And Capex Coverage Ratio is likely to grow to 1.08. As of 01/12/2026, Common Stock Shares Outstanding is likely to drop to about 51.2 M.
Aspire BioPharma Workforce Comparison
Aspire BioPharma is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 178. Aspire BioPharma adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Aspire BioPharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aspire BioPharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aspire BioPharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aspire BioPharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fell Donald G. over a month ago Acquisition by Fell Donald G. of 10500 shares of Aspire BioPharma, at 0. subject to Rule 16b-3 | ||
Fell Donald G. over three months ago Acquisition by Fell Donald G. of 9500 shares of Aspire BioPharma, at 0. subject to Rule 16b-3 | ||
Fell Donald G. over six months ago Disposition of 10500 shares by Fell Donald G. of Aspire BioPharma, at 0. subject to Rule 16b-3 | ||
Fell Donald G. over six months ago Disposition of 9500 shares by Fell Donald G. of Aspire BioPharma, at 0. subject to Rule 16b-3 |
Aspire BioPharma Notable Stakeholders
An Aspire BioPharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aspire BioPharma often face trade-offs trying to please all of them. Aspire BioPharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aspire BioPharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Howe | CEO Director | Profile | |
| Kraig Higginson | President Board | Profile | |
| Stephen Quesenberry | Corporate Counsel | Profile | |
| Ernest Scheidemann | Chief Officer | Profile |
About Aspire BioPharma Management Performance
The success or failure of an entity such as Aspire BioPharma often depends on how effective the management is. Aspire BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aspire management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aspire management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (97.43) | (92.56) | |
| Return On Capital Employed | 2.31 | 2.71 | |
| Return On Assets | (97.43) | (92.56) | |
| Return On Equity | 7.33 | 7.69 |
Aspire BioPharma Workforce Analysis
Traditionally, organizations such as Aspire BioPharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aspire BioPharma within its industry.Aspire BioPharma Manpower Efficiency
Return on Aspire BioPharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.1M | |
| Net Loss Per Executive | 3.1M |
Additional Tools for Aspire Stock Analysis
When running Aspire BioPharma's price analysis, check to measure Aspire BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma is operating at the current time. Most of Aspire BioPharma's value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma's price. Additionally, you may evaluate how the addition of Aspire BioPharma to your portfolios can decrease your overall portfolio volatility.